- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
Biocon is engaged in the business of manufacture of biotechnology products and research services.(Source : 202003-01 Annual Report Page No:195)
Biocon's subsidiary received marketing approval for its pegfilgrastim biosimilar in Japan. This strengthens Biocon's portfolio there. Sandoz K.K. will exclusively promote and distribute the product, expanding patient access to high-quality, affordable medications.
Biocon's US subsidiary secured FDA approval for Yesintek® (ustekinumab-kfce) single-dose autoinjectors. This new delivery format expands patient treatment options for autoimmune diseases, significantly strengthening Biocon's immunology presence in the US market.
Biocon management is scheduled to participate in 1x1/Group/In-Person meetings with analysts and institutional investors at the Motilal Oswal 22nd Annual Global Investor Conference on August 17, 2026, in Mumbai. The company will not disclose any Unpublished Price Sensitive Information (UPSI) during these interactions.